FIELD: ophthalmological oncology. SUBSTANCE: recombinant interleukin-2 (Ronkoleukin) is injected intravenously in dropwise manner in dose 1-1.5 mln Un. , 5 infusions in one course. If regression of tumor and/or metastases is insufficient, the courses are repeated. EFFECT: enabled destruction or diminishing of dimensions of primary or and/or metastatic tumor nodule up to complete regression allowing preservation of eye as organ. 2 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING UVEAL MELANOMA | 2000 |
|
RU2169006C1 |
METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 1999 |
|
RU2157998C1 |
METHOD OF REVEALING LATENT METASTATIC SPREAD IN PATIENTS WITH UVEAL MELANOMA | 1998 |
|
RU2147373C1 |
METHOD FOR PREDICTING UVEITIC MELANOMA CLINICAL COURSE | 1999 |
|
RU2149404C1 |
METHOD FOR PREDICTING CLINICAL FLOW OF UVEAL MELANOMA | 2001 |
|
RU2193200C1 |
METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 2001 |
|
RU2197731C2 |
METHOD FOR PREDICTING CLINICAL DEVELOPMENT COURSE OF UVEAL MELANOMA | 2001 |
|
RU2192812C1 |
METHOD FOR PREDICTING CLINICAL DEVELOPMENT COURSE OF UVEAL MELANOMA | 1998 |
|
RU2146823C1 |
METHOD OF CHOROID MELANOME TREATMENT | 2006 |
|
RU2359648C2 |
METHOD FOR SETTING DIFFERENTIAL DIAGNOSIS OF LEIOMYOMA AND IRIS MELANOMA | 2001 |
|
RU2199124C1 |
Authors
Dates
2001-10-27—Published
2000-09-27—Filed